Aier Eye Hospital Group Co., Ltd.

SZSE:300015 Stock Report

Market Cap: CN¥130.7b

Aier Eye Hospital Group Valuation

Is 300015 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300015 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300015 (CN¥14.06) is trading below our estimate of fair value (CN¥18.54)

Significantly Below Fair Value: 300015 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300015?

Key metric: As 300015 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300015. This is calculated by dividing 300015's market cap by their current earnings.
What is 300015's PE Ratio?
PE Ratio36x
EarningsCN¥3.63b
Market CapCN¥130.72b

Price to Earnings Ratio vs Peers

How does 300015's PE Ratio compare to its peers?

The above table shows the PE ratio for 300015 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average99.2x
301267 Huaxia Eye Hospital GroupLtd
33x22.4%CN¥17.5b
301293 Sanbo Hospital Management Group
93.3xn/aCN¥10.2b
002219 New Journey Health Technology GroupLTD
191.9xn/aCN¥9.6b
300143 INKON Life Technology
78.4x33.3%CN¥7.0b
300015 Aier Eye Hospital Group
36x14.6%CN¥130.7b

Price-To-Earnings vs Peers: 300015 is good value based on its Price-To-Earnings Ratio (36x) compared to the peer average (99.2x).


Price to Earnings Ratio vs Industry

How does 300015's PE Ratio compare vs other companies in the CN Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300015 36.0xIndustry Avg. 33.5xNo. of Companies7PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300015 is expensive based on its Price-To-Earnings Ratio (36x) compared to the CN Healthcare industry average (33.5x).


Price to Earnings Ratio vs Fair Ratio

What is 300015's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300015 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio36x
Fair PE Ratio33.7x

Price-To-Earnings vs Fair Ratio: 300015 is expensive based on its Price-To-Earnings Ratio (36x) compared to the estimated Fair Price-To-Earnings Ratio (33.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300015 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥14.06
CN¥15.42
+9.7%
23.8%CN¥20.64CN¥7.00n/a13
Dec ’25CN¥14.68
CN¥15.19
+3.5%
24.1%CN¥20.64CN¥7.00n/a13
Nov ’25CN¥14.18
CN¥14.24
+0.4%
26.5%CN¥20.64CN¥7.00n/a13
Oct ’25CN¥15.91
CN¥13.43
-15.6%
25.8%CN¥20.64CN¥7.00n/a13
Sep ’25CN¥9.70
CN¥14.36
+48.0%
29.0%CN¥22.50CN¥7.00n/a13
Aug ’25CN¥10.89
CN¥15.97
+46.6%
21.5%CN¥22.50CN¥9.80n/a13
Jul ’25CN¥10.39
CN¥17.73
+70.6%
18.1%CN¥24.60CN¥13.50n/a13
Jun ’25CN¥12.12
CN¥17.71
+46.1%
18.2%CN¥24.60CN¥13.50n/a13
May ’25CN¥12.90
CN¥19.23
+49.1%
26.5%CN¥31.87CN¥13.50n/a13
Apr ’25CN¥13.13
CN¥23.26
+77.2%
15.3%CN¥31.87CN¥18.70n/a13
Mar ’25CN¥14.45
CN¥23.52
+62.8%
15.1%CN¥31.87CN¥18.70n/a14
Feb ’25CN¥13.03
CN¥23.80
+82.7%
12.7%CN¥28.80CN¥18.70n/a13
Jan ’25CN¥15.82
CN¥24.37
+54.0%
10.0%CN¥28.80CN¥20.00n/a13
Dec ’24CN¥17.00
CN¥25.52
+50.1%
13.5%CN¥35.00CN¥21.00CN¥14.6813
Nov ’24CN¥18.42
CN¥25.52
+38.5%
13.5%CN¥35.00CN¥21.00CN¥14.1813
Oct ’24CN¥17.97
CN¥26.89
+49.6%
11.8%CN¥35.00CN¥22.00CN¥15.9113
Sep ’24CN¥18.30
CN¥27.12
+48.2%
11.1%CN¥35.00CN¥22.00CN¥9.7013
Aug ’24CN¥20.03
CN¥30.42
+51.9%
11.8%CN¥36.30CN¥26.00CN¥10.8912
Jul ’24CN¥18.55
CN¥30.26
+63.1%
10.3%CN¥36.30CN¥26.00CN¥10.3912
Jun ’24CN¥20.95
CN¥30.80
+47.0%
9.8%CN¥36.92CN¥26.84CN¥12.1212
May ’24CN¥22.66
CN¥30.89
+36.3%
9.7%CN¥36.92CN¥26.84CN¥12.9012
Apr ’24CN¥23.90
CN¥31.24
+30.7%
13.0%CN¥38.46CN¥23.08CN¥13.1313
Feb ’24CN¥26.04
CN¥30.85
+18.5%
12.5%CN¥37.46CN¥23.08CN¥13.0313
Jan ’24CN¥23.90
CN¥30.10
+26.0%
13.7%CN¥37.46CN¥23.08CN¥15.8213
Dec ’23CN¥21.78
CN¥30.16
+38.5%
14.2%CN¥37.46CN¥23.08CN¥17.0012

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 14:11
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aier Eye Hospital Group Co., Ltd. is covered by 46 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Siti Bte SalikinCFRA Equity Research
Songtao YEChangjiang Securities Co. LTD.